FDA has approved Omvoh™ infusion, the first and only IL-23p19 antagonist for the treatment of moderately to severely active ulcerative colitis in adults.
Eli Lilly and Company announced today that the U.S. FDA has approved Omvoh™ (mirikizumab-mrkz) infusion (300 mg/15 mL)/injection (100 mg/mL), the first and only interleukin-23p19 (IL-23p19) antagonist for the treatment of moderately to severely active ulcerative colitis (UC) in adults.…
